Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Inspire Investing LLC

Inspire Investing LLC lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 40.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,242 shares of the medical research company’s stock after purchasing an additional 4,096 shares during the quarter. Inspire Investing LLC’s holdings in Edwards Lifesciences were worth $1,054,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AE Wealth Management LLC raised its stake in Edwards Lifesciences by 14.8% during the second quarter. AE Wealth Management LLC now owns 4,618 shares of the medical research company’s stock worth $427,000 after purchasing an additional 594 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Edwards Lifesciences by 42.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 932 shares of the medical research company’s stock worth $86,000 after buying an additional 280 shares during the period. Public Sector Pension Investment Board raised its position in shares of Edwards Lifesciences by 73.6% in the 2nd quarter. Public Sector Pension Investment Board now owns 23,267 shares of the medical research company’s stock worth $2,149,000 after buying an additional 9,863 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its holdings in Edwards Lifesciences by 58.5% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 115,167 shares of the medical research company’s stock valued at $10,638,000 after acquiring an additional 42,527 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Edwards Lifesciences during the second quarter worth about $182,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on EW. Canaccord Genuity Group lifted their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Stifel Nicolaus increased their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a research report on Thursday, December 5th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the company from $82.00 to $90.00 in a report on Monday, December 16th. Finally, JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $78.48.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $68.95 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm’s 50-day simple moving average is $72.25 and its 200-day simple moving average is $70.86. The firm has a market cap of $40.66 billion, a PE ratio of 9.95, a price-to-earnings-growth ratio of 3.59 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.59 earnings per share. Equities analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,000 shares of company stock worth $2,195,180. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.